AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • November 9th, 2020 • Homology Medicines, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of July 28, 2017, by and among Homology Medicines, Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto (each, an “Investor,” and together with any subsequent investors, or transferees, who become parties hereto as “Investors” in accordance with the terms hereof, the “Investors”), and, solely for purposes of Section 2 (other than Subsections 2.1 and 2.10), Subsection 4.1 and Section 6 (other than Subsection 6.6), California Institute of Technology (“Caltech”).
SECOND AMENDMENT TO COLLABORATION AND LICENSE AgreementCollaboration and License Agreement • November 9th, 2020 • Homology Medicines, Inc. • Pharmaceutical preparations
This Second Amendment to Collaboration and License Agreement (the “Second Amendment”), is entered into as of October 30, 2020 (the “Second Amendment Effective Date”) by and between Homology Medicines, Inc., a corporation organized under the laws of the State of Delaware, having a business address at One Patriots Park, Bedford, MA 01730 (“HMI”), and Novartis Institutes for BioMedical Research, Inc., a corporation organized under the laws of the State of Delaware, having a business address at 250 Massachusetts Avenue, Cambridge, MA 02139 (“NVS”). HMI and NVS are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
